A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers

AIDS Research and Human Retroviruses
Vadakkuppatu Devasenapathi RamanathanP Fast

Abstract

A recombinant modified vaccinia Ankara virus vaccine candidate (TBC-M4) expressing HIV-1 subtype C env, gag, tat-rev, and nef-RT genes was tested in a randomized, double-blind, dose escalation Phase I trial in 32 HIV-uninfected healthy volunteers who received three intramuscular injections of TBC-M4 at 0, 1, and 6 months of 5 x 10(7) plaque-forming units (pfu) (low dosage, LD) (n = 12) or 2.5 x 10(8) pfu (high dosage, HD) (n = 12) or placebo (n = 8). Local and systemic reactogenicity was experienced by approximately 67% and 83% of vaccine recipients, respectively. The reactogenicity events were mostly mild in severity. Severe but transient systemic reactogenicity was seen in one volunteer of the HD group. No vaccine-related serious adverse events or events suggesting perimyocarditis were seen. A higher frequency of local reactogenicity events was observed in the HD group. Cumulative HIV-specific IFN-gamma ELISPOT responses were detected in frozen PBMCs from 9/11 (82%), 12/12 (100%), and 1/8 (13%) volunteers after the third injection of the LD, HD, and placebo groups, respectively. Most of the responses were to gag and env proteins (maximum of 430 SFU/10(6) PBMCs) persisting across multiple time points. HIV-specific ELISA antibo...Continue Reading

References

Dec 24, 1997·JAMA : the Journal of the American Medical Association·R C BollingerT C Quinn
Mar 18, 2000·Antimicrobial Agents and Chemotherapy·C J PetropoulosJ M Whitcomb
Feb 13, 2002·International Journal of STD & AIDS·A K SahniP Seth
Mar 27, 2004·Current HIV Research·Paul Spearman
May 4, 2004·Journal of the American College of Cardiology·Dimitri C CassimatisMarina N Vernalis
Jul 6, 2004·Journal of the American College of Cardiology·Robert E EckartUNKNOWN Department of Defense Smallpox Vaccination Clinical Evaluation Team
Jul 10, 2004·AIDS Research and Human Retroviruses·James M SmithHarriet L Robinson
Dec 17, 2005·Nature Immunology·Wayne C KoffRonald C Desrosiers
Sep 9, 2006·Journal of Immunological Methods·Zoe MoodieSteven G Self
Oct 13, 2006·Advanced Drug Delivery Reviews·Richard HarropMiles W Carroll
Nov 17, 2006·The Journal of Infectious Diseases·Andrew T CatanzaroUNKNOWN Vaccine Research Center 006 Study Team
Jan 19, 2007·The Journal of Infectious Diseases·Swati B GuptaWalter L Straus
Mar 30, 2007·Vaccine·Andrew T CatanzaroUNKNOWN VRC 007 Study Team
Jul 10, 2007·Lancet·Seth Franklin Berkley, Wayne Chester Koff
Aug 7, 2007·AIDS Research and Human Retroviruses·Iram Fatima KhanPradeep Seth
Jan 16, 2008·The Journal of Experimental Medicine·Alexandre HarariGiuseppe Pantaleo
Feb 21, 2008·AIDS Research and Human Retroviruses·Suganya SelvarajahDennis R Burton
Apr 23, 2008·The Journal of Experimental Medicine·Paul A GoepfertEric Hunter
Apr 25, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Frances H PriddyUNKNOWN Merck V520-016 Study Group
May 7, 2008·The Journal of Experimental Medicine·Todd M Allen, Marcus Altfeld
May 10, 2008·Science·Bruce D Walker, Dennis R Burton
Jun 7, 2008·Nature Medicine·David I WatkinsWayne C Koff
Sep 24, 2008·The Journal of Infectious Diseases·Eric SandströmUNKNOWN HIV Immunogenicity Study 01/02 Team
Jul 1, 2006·Current Opinion in HIV and AIDS·Patricia E Fast

❮ Previous
Next ❯

Citations

Sep 30, 2010·PLoS Medicine·Stephen J KentUNKNOWN AIDS Vaccine for Asia Network investigators and supporters
Aug 23, 2011·Expert Review of Vaccines·Stephen R Walsh, Raphael Dolin
Aug 24, 2012·Expert Review of Vaccines·Sorachai NitayaphanJean-Louis Excler
Oct 31, 2013·Expert Review of Vaccines·Carmen Elena GómezMariano Esteban
Sep 13, 2015·International Journal of Biological Macromolecules·Seema P AjbaniAtmaram H Bandivdekar
Jun 25, 2015·AIDS Research and Human Retroviruses·Nittaya PhanuphakJean Louis Excler
May 15, 2013·Microbiology and Immunology·Subha DamodharanRamakrishnan Usha
Oct 22, 2013·Human Vaccines & Immunotherapeutics·Seema SahaySanjay Mehendale
Aug 22, 2012·Human Vaccines & Immunotherapeutics·Carmen Elena GómezMariano Esteban
Jan 1, 2014·Human Vaccines & Immunotherapeutics·Claudia SchmidtPatricia E Fast
Oct 29, 2013·Vaccine·Richard StebbingsGérald Voss
Jun 8, 2013·Current Opinion in HIV and AIDS·Jean-Louis ExclerNina D Russell
Aug 26, 2017·Expert Review of Vaccines·Lynette Siv Chea, Rama Rao Amara
Dec 15, 2020·The Indian Journal of Tuberculosis· National Institute For Research In Tuberculosis Formerly Tuberculosis Research Centre Icmr-Nirt Chennai, Srikanth Tripathy

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
ELISA

Software Mentioned

BD
CellQuest

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.